Show simple item record

Authordc.contributor.authorSharma, S. 
Authordc.contributor.authorBabiker, A.G. 
Authordc.contributor.authorEmery, S. 
Authordc.contributor.authorGordin, F.M. 
Authordc.contributor.authorLundgren, J.D. 
Authordc.contributor.authorNeaton, J.N. 
Authordc.contributor.authorBakowska, E. 
Authordc.contributor.authorSchechter, M. 
Authordc.contributor.authorWiselka, M.J. 
Authordc.contributor.authorWolff Reyes, Marcelo 
Cita de ítemdc.identifier.citationHIV Medicine (2015), 16 (Suppl. 1), 30–36en_US
Identifierdc.identifier.otherDOI: 10.1111/hiv.12231
General notedc.descriptionArtículo de publicación ISIen_US
Abstractdc.description.abstractObjectives The risks and benefits of initiating antiretroviral treatment (ART) at high CD4 cell counts have not been reliably quantified. The Strategic Timing of AntiRetroviral Treatment (START) study is a randomized international clinical trial that compares immediate with deferred initiation of ART for HIV-positive individuals with CD4 cell counts above 500 cells/μL. We describe the demographics, HIV-specific characteristics and medical history of this cohort. Methods Data collected at baseline include demographics, HIV-specific laboratory values, prior medical diagnoses and concomitant medications. Baseline characteristics were compared by geographical region, gender and age. Results START enrolled 4685 HIV-positive participants from 215 sites in 35 countries. The median age is 36 years [interquartile range (IQR) 29–44 years], 27% are female, and 45% self-identify as white, 30% as black, 14% as Latino/Hispanic, 8% as Asian and 3% as other. The route of HIV acquisition is reported as men who have sex with men in 55% of participants, heterosexual sex in 38%, injecting drug use in 1% and other/unknown in 5%. Median time since HIV diagnosis is 1.0 year (IQR 0.4–3.0 years) and the median CD4 cell count and HIV RNA values at study entry are 651 cells/μL (IQR 584–765 cells/μL) and 12 754 HIV RNA copies/mL (IQR 3014–43 607 copies/mL), respectively. Conclusions START has enrolled a diverse group of ART-naïve individuals with high CD4 cell counts who are comparable to the HIV-positive population from the regions in which they were enrolled. The information collected with this robust study design will provide a database with which to evaluate the risks and benefits of early ART use for many important outcomes.en_US
Publisherdc.publisherBritish HIV Associationen_US
Type of licensedc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
Link to Licensedc.rights.uri*
Keywordsdc.subjectClinical trialen_US
Keywordsdc.subjectSTART trialen_US
Keywordsdc.subjectWhen to start antiretroviral therapyen_US
Títulodc.titleDemographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialen_US
Document typedc.typeArtículo de revistaen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 Chile
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 Chile